Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

Fig. 2

Mean changes from baseline in total PsA-modified SHS by PASDAS-defined disease activity state. Results are shown at week 24 (a) and week 52 (b). HDA, high disease activity; IV, intravenous; LDA, low disease activity; ModDA, moderate disease activity; PASDAS, Psoriatic ArthritiS Disease Activity Score; PsA, psoriatic arthritis; SD, standard deviation, SHS, Sharp/van der Heijde score

Back to article page
\